AI assistant
Marksans Pharma Ltd. — Earnings Release 2026
May 26, 2026
62142_rns_2026-05-26_1e09e56c-4cd3-4b76-9529-fac1deaecc3f.pdf
Earnings Release
Open in viewerOpens in your device viewer
M
Marksans Pharma Ltd.
Date: May 26, 2026
BSE Limited
Corporate Relation Department
Phiroze Jeejeeboi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404
National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS
Sub: Press Release
Dear Sir/Madam,
Kindly find enclosed herewith a Press Release in relation to the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026.
Further, as per Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said press release will also be available on the website of the Company i.e., https://www.marksanspharma.com/press-release.html.
We request you to take the aforesaid on record.
Thanking You.
Yours faithfully,
For Marksans Pharma Limited
H
PANIGRAHI
Digitally signed
by H PANIGRAHI
Date: 2026.05.26
12:27:49 +05'30'
Harshavardhan Panigrahi
Company Secretary
Encl: As above
Marksans Pharma Ltd.
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000
E-mail: [email protected]
www.marksanspharma.com
M
Marksans Pharma Ltd.
Q4 & FY26 Financial Results
Marksans Pharma Marksans Pharma Hits Historic Triple: Highest Revenue, EBITDA & PAT ₹3,000 Cr Net Income Guidance Delivered
Mumbai, May 26, 2026 – Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) reported the financial results today for the quarter and full-year ended on March 31, 2026.
Mark Saldanha, Managing Director of the Company, said, "FY26 has been a milestone year for Marksans Pharma, we successfully delivered on our guidance with highest-ever total income at ₹3,033 crore, EBITDA at ₹601 crore (margin 20.4%) and an all-time high PAT of ₹420 crore.
Growth was led by a series of new launches across markets through the year, including our Rx branded portfolio in Australia. UK delivered a very strong recovery in Q4 achieving its highest-ever quarterly revenue. Growth was also aided by 112 new SKUs launched in the US market. We also strengthened our global footprint by entering new markets including Germany, Canada, and Ireland.
We closed the year with a cash balance of ₹990 crore, extending our multi-year track record of net cash positive, with the major capex cycle now nearly complete.
While we are monitoring emerging input cost pressures closely, our underlying momentum, balance sheet strength, and disciplined execution position us well to continue delivering sustainable growth and long-term shareholder value."
FY26 Financial Highlights
- Total Income stood at Rs. 3,033 cr., up by 12.8% YoY
- Gross profit came in at Rs. 1,674 cr., up by 13.2% YoY, with a gross margin of 56.7%
- EBITDA stood at Rs. 601 cr. with an EBITDA margin of 20.4%
- EPS was at Rs. 9.2
Q4FY26 Financial Highlights
- Total Income stood at Rs. 891 cr., up by 23.1% YoY
- Gross profit stood at Rs. 466 cr., up by 21.5% YoY, with gross margin of 54.4%
- EBITDA stood at Rs. 195 cr., with a margin of 22.8%
- EPS was at Rs. 3.3
Business Highlights
US Market
- US & North America Formulation business reported revenues of Rs. 406 cr. in Q4FY26 Rs. 1,533 cr. in FY26
- Revenue scaled 2.4x from FY22 to FY26, reflecting consistent execution across the period
- Strong product engine: 100+ products manufactured and distributed, with 112 new SKUs launched in FY26 and 51 products in pipeline
UK and Europe Market
- Revenues from the UK & Europe Formulation business in Q4FY26 stood at Rs. 308 cr. and Rs. 1015 cr. in FY26. Q4 momentum driven by multiple new product launches and improved order flow
- Price erosion in UK products has stabilized in Q4FY26
- Strong regulatory pipeline: 18 products approved and 30 filings done in FY26; 24 products awaiting approval as of 31st March 2026; 200+ products to be filed over the next 4 years
Australia and New Zealand Market
- Australia and New Zealand businesses reported revenues of Rs. 123 cr. in Q4FY26 and Rs. 303 cr. in FY26
- Highest-ever quarterly performance, more than doubling sequentially from Q3. Increase driven by new launches and healthy volume growth
- Launched Branded Prescription Division – Nova Pharma
- 11 Rx brands launched in FY26 under Nova Pharma
RoW Market
- RoW business reported revenues of Rs. 19 cr. in Q4FY26 and Rs. 99 cr. in FY26. RoW performance impacted by ongoing geopolitical disruptions. Order fulfilment constrained by logistics challenges; deliveries deferred to subsequent quarters
Other Highlights
- Cash generated from operations at ₹ 458 cr during FY26
- Capex of ₹ 131 cr incurred during FY26 on net basis
- Working capital cycle ~138 days for FY26
- Cash balance of ₹ 990 cr as on 31st March 2026
- Research & development (R&D) spends at ₹ 89 cr in FY26, 3.0% of consolidated revenue
Business Performance
Consolidated profit and loss statement:
| Particulars | Q4FY26 | Q4FY25 | Q3FY26 | YoY | QoQ | FY26 | FY25 | YoY |
|---|---|---|---|---|---|---|---|---|
| Net Income | 891.3 | 723.8 | 774.6 | 23.1% | 15.1% | 3,033.5 | 2,689.2 | 12.8% |
| Operating Revenue | 856.1 | 708.5 | 754.4 | 20.8% | 13.5% | 2,950.9 | 2,622.8 | 12.5% |
| Gross Profit | 465.5 | 383.2 | 438.2 | 21.5% | 6.2% | 1,673.7 | 1,479.1 | 13.2% |
| Gross margin | 54.4% | 54.1% | 58.1% | 27 bps | -372bps | 56.7% | 56.4% | 32 bps |
| EBITDA | 195.4 | 126.9 | 160.7 | 54.0% | 21.6% | 600.8 | 532.7 | 12.8% |
| EBITDA Margin | 22.8% | 17.9% | 21.3% | 491 bps | 152 bps | 20.4% | 20.3% | 5 bps |
| PAT | 149.0 | 90.7 | 113.7 | 64.3% | 31.1% | 420.1 | 382.6 | 9.8% |
| Net Margin | 16.7% | 12.5% | 14.7% | 419 bps | 204 bps | 13.8% | 14.2% | -38 bps |
| EPS (Rs.) | 3.3 | 2.0 | 2.5 | 63.6% | 30.9% | 9.2 | 8.4 | 9.8% |
All figures in Rs. Cr. unless otherwise stated
Note:
1) Net Income Margin = Net profit / Total Income (Revenue from operations + Other Income
2) Following a review of consolidated financial statement groupings, minor reclassifications have been made to Q4 and FY25 comparatives. These are classification adjustments only and do not impact reported profitability
Business-wise performance:
| Particulars | Q4FY26 | Q4FY25 | YoY | FY26 | FY25 | YoY | Mix |
|---|---|---|---|---|---|---|---|
| US & North America | 406.2 | 328.6 | 23.6% | 1,533.5 | 1,236.6 | 24.0% | 52.0% |
| UK and Europe | 307.7 | 274.1 | 12.3% | 1,015.0 | 1,029.8 | -1.4% | 34.4% |
| Australia & NZ | 123.4 | 76.5 | 61.3% | 303.1 | 252.8 | 19.9% | 10.3% |
| Rest of World (ROW) | 18.9 | 29.3 | -35.7% | 99.4 | 103.7 | -4.1% | 3.4% |
| Revenue from operations | 856.1 | 708.5 | 20.8% | 2,950.9 | 2,622.8 | 12.5% | 100.0% |
All figures in Rs. Cr. unless otherwise stated
Earnings Conference Call:
There will be an Earnings conference call at 4:30 pm IST on May 27, 2026, during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.marksanspharma.com.
| Date and Time | May 27, 2026, at 4:30 pm IST |
|---|---|
| Diamond pass link | Link |
| Primary Access Numbers | +91 22 6280 1384, +91 22 7115 8285 |
| International Toll-Free Numbers | US: 18667462133 |
| UK: 08081011573 | |
| Singapore: 8001012045 | |
| Hong Kong: 800964448 |
About Marksans Pharma Ltd
Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.
Disclaimer
Certain statements in this press release may contain forward-looking statements, including, but not limited to, statements regarding the Company's business strategies, operations, financial condition, and future performance. These forward-looking statements are based on current expectations, assumptions, and estimates, and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
Contact Information
Jitendra Sharma, CFO
Marksans Pharma Ltd
Tel: +91 022 40012000
[email protected]
Registered Office
11th Floor, "GRANDEUR"
Off Veera Desai Extension Road
Oshiwara, Andheri West
Mumbai, Maharashtra, 400 053
Telephone: +91 224001 2000
Fax: +91 224001 2011
CIN: L24110MH1992PLC066364
ISIN: INE750C01026
NSE Code: MARKSANS
BSE CODE: 524404
Website: http://www.marksanspharma.com